Should Shares CRISPR Therapeutics Be a February Pick?
Biotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Stock index values update on scheduled times or upon data arrivals, varying by index and exchange. This piece covers the timing and implications.
22,965 articlesBiotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
A large holder trimmed a substantial stake in a biotech name while the stock advanced. This piece explains what inves...
A bold, high‑risk biotech bet can pay off with patience and discipline. This article breaks down iovance biotherapeut...
Adobe sits as a candidate undervalued stock that could rebound in 2026, trading in the low-$280s with a 16x trailing ...
Chevron has kept its promise to shareholders with steady cash returns. Discover how 16 quarters of returns totaling o...
When Occidental Petroleum faced a retreat in stock price, traders asked whether it was a one-off event or a signal. T...
Figma stunned traders with a big Q1 2026 beat, lifting the stock on Friday morning. Here’s what happened, why it matt...
As AI accelerates, a pair of blue-chip picks stands out for a decade-long hold. Learn why these two AI leaders fit th...
When a Planet Labs CEO sells shares, investors take note. This article breaks down what the move could signal, how to...
As Netflix stumbles, investors wonder if Disney down 2026 offers a rare contrarian opportunity. This article digs int...
When a company’s founder or CEO sells a chunk of stock, it sparks questions. This article breaks down the Zoom inside...
A new Belden stake filed with the SEC shows an investment firm buying $89.5 million worth of shares. This article bre...